Tirzepatide investigated for antidepressant effects in mouse model of chronic stress-induced depression

The complex interplay between depression, diabetes, and obesity forms a challenging "metabolic-mood syndrome," often marked by systemic inflammation, impaired neuroplasticity, and neuroendocrine dysregulation. Current antidepressant therapies frequently exhibit limited efficacy in these comorbid conditions and can sometimes worsen metabolic profiles. Tirzepatide, a dual GLP-1R and GIPR agonist, is approved for type 2 diabetes and obesity, and its known metabolic benefits suggest a potential for broader neuropsychiatric applications by addressing underlying inflammatory and metabolic pathways.

Forty male Swiss Albino mice were randomly assigned to five groups, each with n = 8 animals. The study utilized an unpredictable chronic mild stress (UCMS) model to induce depression-like behaviors. Groups included a normal control, a disease control (UCMS + saline), and a positive control (UCMS + fluoxetine 10 mg/kg). Two test groups received UCMS + tirzepatide at 50 μg/kg and 120 μg/kg, respectively. The abstract is truncated and does not specify the route of administration, frequency, duration of treatment, or the primary behavioral and biochemical endpoints used to assess antidepressant-like effects.

The provided abstract is truncated and does not contain the results section of the study. Therefore, specific findings regarding the antidepressant-like effects of tirzepatide, including any statistical significance, percentage changes, or comparisons to control groups, cannot be reported. The study's objective was to evaluate these effects, but the outcomes are not detailed in the available text.